7 news items
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BNTX
GMAB
1 Jun 24
investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BNTX
GMAB
1 Jun 24
in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory
Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More
AMGN
BNTX
MRK
24 May 24
., executive vice president, Research and Development, and chief scientific officer at Amgen
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
BNTX
21 May 24
of BioNTech's research and development programs in oncology, including the targeted timing and number of additional potentially registrational trials
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
BNTX
17 May 24
; BioNTech's research and development programs, including statements characterizing timing, related preparatory work, and the availability of results
zr3qbobe6 jgwr0
BNTX
6 May 24
of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements
d78s9aye8byc86my8l25bcqeti1mor4frzzgl6bwb 48d1qtiyy27fubidzg
BNTX
7 Apr 24
autogene cevumeran (BNT122, RO7198457); the initiation, timing, progress and results of BioNTech's research and development programs in oncology
- Prev
- 1
- Next